Moses & Singer's Healthcare Group Successfully Represents AIT Therapeutics, Inc. in Negotiating Its Commercial Licensing Deal with Circassia

January 24, 2019

A team from Moses & Singer LLP, led by Jill Anderson, partner in the firm's  Healthcare and Privacy & CyberSecurity practice groups, represented AIT Therapeutics, a clinical-stage medical device and biopharmaceutical company in connection with their $32.5 million commercial licensing agreement. As part of the deal, AIT grants Circassia an exclusive license for the commercialization of AIT’s nitric oxide generator and delivery system for the treatment of persistent pulmonary hypertension of the newborn (PPHN) and related indications at concentrations of < 80 ppm in the hospital setting in the United States and China.

For more information, please click here.